Willis Towers Watson PLC (NASDAQ: WLTW) appears poised to generate higher-than-expected organic revenue growth in the second quarter and could raise full-year EPS guidance, according to Wells Fargo.
Elyse Greenspan upgraded Willis Towers Watson from Market Perform to Outperform and raised the price target from $175 to $220.
Willis Towers Watson faces easy comps for organic revenue growth in the second quarter and may record around $24 million in the human capital and benefits segment in the second and third quarters due to accounting changes, Greenspan said in a Wednesday upgrade note. (See her track record here.)
The $24 million from revenue recognition accounting changes positions the company to beat Wells Fargo's second-quarter organic revenue growth estimate of 4% as well as the full-year outlook, the analyst said.
The Street estimates for 2019 do not accurately reflect the impact of the company's acquisition of the direct-to-consumer health care organization TRANZACT, she said.
Wells Fargo expects Willis Towers Watson to raise its 2019 EPS guidance to reflect TRANZACT, a deal that is likely to be accretive to full-year figures “as the business earnings all [come] in Q4.”
Wells Fargo left its 2019 EPS estimate unchanged at $11, and Greenspan said the figure is already higher than Willis Towers Watson's guidance of $10.60-$10.85.
Wells Fargo raised its 2020 and 2021 EPS estimates from $11.75 to $11.95 and from $12.75 to $13.10, respectively, to reflect stronger revenue growth.
Willis Towers Watson stock was up 0.25% at $196.10 at the time of publication Thursday.
Benzinga's Top Upgrades, Downgrades For July 11, 2019
10 Biggest Price Target Changes For Tuesday
Latest Ratings for WLTW
|Jul 2019||Upgrades||Market Perform||Outperform|
View More Analyst Ratings for WLTW
View the Latest Analyst Ratings
See more from Benzinga
- Applied Materials Launches Next Generation Of Memory Design: 'A New Vector Of Innovation'
- Helen Of Troy Begins Fiscal Year With A Big Quarterly Beat, BofA Raises Estimates
- Analyst: CytomX Therapeutics Validated By AbbVie Decision
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.